Clinical Trial Search

Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants

Primary: Summary of Influenza Seroprotection Post-vaccination With Fluzone® Vaccine. — 44; 34; 31; 74 Percentage of Participants

Primary: Plasma Uric Acid Responder — 80; 72; 60; 12 Participants — p=0.0009

Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 — -1.34; -1.62; -0.28 Percentage of hemoglobin — p=<0.001

Primary: Number of Responders at Week 6 — 9; 0; 6; 8 Participants

Primary: Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period — 21; 69; 62 Participants — p=0.026

Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12. — 5.2; 5.3; 7.7 Percent of predicted FEV1 — p=0.2696

Primary: Difference in Sensitivity of Lesion Detection in MRI Images (Post-contrast MRI Minus Pre-contrast MRI) Measured as Percentage Points — 8.65; 12.23; 7.50 Percentage points

Primary: Change From Baseline to Week 1 in Weekly Mean of the 24-hour Average Pain Scores — -0.54; -0.53; -0.71; -0.39 units on a scale — p=0.503

Primary: Treatment Response at Week 48 — 34.5; 15 percentage of participants — p=0.0001

Primary: First Hospitalization for Cardiovascular Reason or Death From Any Cause — 734; 917 participants — p=<0.0001

Primary: The Grades of the Number of Duodenal Contractions — 1.13; 1.17 scores on a scale

Primary: Change From Baseline in HbA1c at Week 52 — -0.67; -0.67 Percent

Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure — -6.48; -9.24; -9.33 mmHg — p=<0.0001

Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 92; 94 Participants